Gefjon Pharma has developed a platform technology with the potential to significantly reduce global antimicrobial consumption, playing a crucial role in combating antimicrobial resistance (AMR) and disrupting protein production by significantly lowering costs.
Our first product is a revolutionary OMV based broad-spectrum bacterial E. coli vaccine targeting poultry production. We have established PoC for both the vaccine and an aerosol application method. With E. coli being the single most significant cause of mortality and infections in poultry production, we will significantly reduce the need for antimicrobials, reduce CO2 emissions and food waste, improve animal welfare, while increasing customer revenues. With our excellent industry network and a strong demand for new vaccines, market entry barriers are low.
Our technology features a genetically modified, hyper-productive, and patentable bacterial strain capable of efficiently and economically expressing and carrying proteins of your choice. Additionally, we have developed a highly effective extraction and production method. The E. coli vaccine is just the beginning!